JP2022506503A5 - - Google Patents
Info
- Publication number
- JP2022506503A5 JP2022506503A5 JP2021523902A JP2021523902A JP2022506503A5 JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5 JP 2021523902 A JP2021523902 A JP 2021523902A JP 2021523902 A JP2021523902 A JP 2021523902A JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- antisense strand
- dsrna agent
- sense strand
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024129696A JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758094P | 2018-11-09 | 2018-11-09 | |
| US62/758,094 | 2018-11-09 | ||
| PCT/US2019/059818 WO2020097044A1 (en) | 2018-11-09 | 2019-11-05 | Modified double stranded oligonucleotides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129696A Division JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506503A JP2022506503A (ja) | 2022-01-17 |
| JP2022506503A5 true JP2022506503A5 (OSRAM) | 2022-09-20 |
| JP7536007B2 JP7536007B2 (ja) | 2024-08-19 |
Family
ID=70612465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523902A Active JP7536007B2 (ja) | 2018-11-09 | 2019-11-05 | 修飾二重鎖オリゴヌクレオチド |
| JP2024129696A Pending JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024129696A Pending JP2024149701A (ja) | 2018-11-09 | 2024-08-06 | 修飾二重鎖オリゴヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12600965B2 (OSRAM) |
| EP (1) | EP3877524A4 (OSRAM) |
| JP (2) | JP7536007B2 (OSRAM) |
| AU (2) | AU2019376628B2 (OSRAM) |
| CA (1) | CA3118537A1 (OSRAM) |
| WO (1) | WO2020097044A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03043B (me) | 2013-03-14 | 2018-10-20 | Alnylam Pharmaceuticals Inc | Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| WO2020097044A1 (en) * | 2018-11-09 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotides |
| TW202526019A (zh) * | 2019-11-13 | 2025-07-01 | 美商阿尼拉製藥公司 | 用於治療血管收縮素原相關病症之方法及組成物 |
| EP4281085A4 (en) * | 2021-01-22 | 2025-12-24 | Alnylam Pharmaceuticals Inc | MODIFIED DOUBLE-STRANDED OLIGONUCLEOTIDES |
| EP4291654A2 (en) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| IL307239A (en) | 2021-03-29 | 2023-11-01 | Alnylam Pharmaceuticals Inc | Preparations containing Huntingtin IRNA factor (HTT) and methods of using them |
| MX2024003519A (es) | 2021-09-24 | 2024-04-01 | Alnylam Pharmaceuticals Inc | Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso. |
| IL315546A (en) | 2022-03-16 | 2024-11-01 | Empirico Inc | GALNAC compositions to improve siRNA bioavailability |
| US12258563B2 (en) | 2022-03-28 | 2025-03-25 | Empirico Inc. | Modified oligonucleotides |
| AU2024217843A1 (en) * | 2023-02-09 | 2025-07-31 | Alnylam Pharmaceuticals, Inc. | Reversir molecules and methods of use thereof |
| WO2026046153A1 (zh) * | 2024-08-26 | 2026-03-05 | 倍臻生物技术（苏州）有限公司 | 修饰的双链核糖核酸及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013013434A2 (pt) * | 2010-12-17 | 2016-08-16 | Arrowhead Res Corp | metade que tem por alvo modulador fármaco cinético em cacho de galactose para sirna |
| IL303831A (en) | 2011-11-18 | 2023-08-01 | Alnylam Pharmaceuticals Inc | Adapted RNAI factors |
| MY167390A (en) | 2011-11-18 | 2018-08-16 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| EA201592225A1 (ru) | 2013-05-22 | 2016-04-29 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
| SG11201602631XA (en) | 2013-10-04 | 2016-05-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the alas1 gene |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| TWI864340B (zh) | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| SG11201703638XA (en) | 2014-11-10 | 2017-06-29 | Alnylam Pharmaceuticals Inc | Hepatitis b virus (hbv) irna compositions and methods of use thereof |
| CA2968114A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| KR20250005546A (ko) | 2015-04-13 | 2025-01-09 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법 |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| JP6896703B2 (ja) | 2015-07-31 | 2021-06-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ＴＴＲ関連疾患を治療または予防するためのトランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物およびその使用方法 |
| MX2018002158A (es) | 2015-08-25 | 2018-07-06 | Alnylam Pharmaceuticals Inc | MíTODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9). |
| JP7129702B2 (ja) | 2016-09-29 | 2022-09-02 | 国立大学法人 東京医科歯科大学 | オーバーハングを有する二本鎖核酸複合体 |
| TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| KR102645243B1 (ko) | 2016-11-23 | 2024-03-11 | 알닐람 파마슈티칼스 인코포레이티드 | 표적외 효과가 감소된 변형 rna 작용제 |
| AU2017376950B2 (en) | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
| SG11201909572QA (en) | 2017-04-18 | 2019-11-28 | Alnylam Pharmaceuticals Inc | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| CA3069868A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof |
| CN112020556A (zh) | 2018-03-21 | 2020-12-01 | 瑞泽恩制药公司 | 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法 |
| MA70658B1 (fr) | 2018-08-13 | 2026-04-30 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation |
| WO2020097044A1 (en) * | 2018-11-09 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Modified double stranded oligonucleotides |
-
2019
- 2019-11-05 WO PCT/US2019/059818 patent/WO2020097044A1/en not_active Ceased
- 2019-11-05 CA CA3118537A patent/CA3118537A1/en active Pending
- 2019-11-05 US US17/291,775 patent/US12600965B2/en active Active
- 2019-11-05 EP EP19882543.2A patent/EP3877524A4/en active Pending
- 2019-11-05 JP JP2021523902A patent/JP7536007B2/ja active Active
- 2019-11-05 AU AU2019376628A patent/AU2019376628B2/en active Active
-
2024
- 2024-08-06 JP JP2024129696A patent/JP2024149701A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259857A patent/AU2025259857A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008283975A5 (OSRAM) | ||
| JP2020188756A5 (OSRAM) | ||
| JP2005517452A5 (OSRAM) | ||
| JP2013535212A5 (OSRAM) | ||
| JP2006502694A5 (OSRAM) | ||
| JP2019141097A5 (OSRAM) | ||
| JP2005524393A5 (OSRAM) | ||
| JP2009060893A5 (OSRAM) | ||
| JP2018512041A5 (OSRAM) | ||
| JP2020500929A5 (OSRAM) | ||
| JP2005517430A5 (OSRAM) | ||
| JP2005517433A5 (OSRAM) | ||
| JP2005517432A5 (OSRAM) | ||
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| WO2015051366A3 (en) | Novel formats for organic compounds for use in rna interference | |
| JP2024105284A5 (OSRAM) | ||
| JP2005517427A5 (OSRAM) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| JP2003520811A5 (OSRAM) | ||
| JP2016116520A5 (OSRAM) | ||
| CA2457528A1 (en) | Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) | |
| WO2005014782A3 (en) | Double-stranded ribonucleic acid with increased effectiveness in an organism | |
| JP2022511550A5 (OSRAM) | ||
| WO2004029212A3 (en) | In vivo gene silencing by chemically modified and stable sirna | |
| JP2013226147A5 (OSRAM) |